Literature DB >> 17249906

Specialty pharmacy cost management strategies of private health care payers.

Debbie Stern1, Debi Reissman.   

Abstract

BACKGROUND: The rate of increase in spending on specialty pharmaceuticals is outpacing by far the rate of increase in spending for other drugs.
OBJECTIVE: To explore the strategies payers are using in response to challenges related to coverage, cost, clinical management, and access of specialty pharmaceuticals and to describe the potential implications for key stakeholders, including patients, physicians, and health care purchasers.
METHODS: Sources of information were identified in the course of providing consulting services in the subject area of specialty pharmaceuticals to health plans, pharmacy benefit managers, employers, and pharmaceutical manufacturers.
RESULTS: Specialty pharmaceuticals represent the fastest growing segment of drug spending due to new product approvals, high unit costs, and increasing use. Health care payers are faced with significant challenges related to coverage, cost, clinical management, and access. A variety of short- and long-term strategies have been employed to address these challenges.
CONCLUSIONS: Current management techniques for specialty pharmaceuticals often represent a stop-gap approach for controlling rising drug costs. Optimum cost and care management methods will evolve as further research identifies the true clinical and economic value of various specialty pharmaceuticals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17249906     DOI: 10.18553/jmcp.2006.12.9.736

Source DB:  PubMed          Journal:  J Manag Care Pharm        ISSN: 1083-4087


  6 in total

1.  Alzheimer's disease: new therapies and the role of biomarkers.

Authors:  Kellie Dudash
Journal:  Biotechnol Healthc       Date:  2011

2.  Addressing Costs and Continuity of Care through Innovative Solutions for Infused Therapies: A Collaborative Experience with Infliximab.

Authors:  Rhett Johnson; Edward N Freeman
Journal:  Am Health Drug Benefits       Date:  2011-01

3.  Medicare formulary coverage for top-selling biologics.

Authors:  Su-Ying Liang; Jennifer S Haas; Kathryn A Phillips
Journal:  Nat Biotechnol       Date:  2009-12       Impact factor: 54.908

4.  Emerging trends in cancer care: health plans' and pharmacy benefit managers' perspectives on changing care models.

Authors:  Rhonda Greenapple
Journal:  Am Health Drug Benefits       Date:  2012-07

5.  Estimating the marginal effect of socioeconomic factors on the demand of specialty drugs.

Authors:  Seyede Sedighe Hosseini Jebeli; Mohsen Barouni; Parvane Heidari Orojloo; Sattar Mehraban
Journal:  Glob J Health Sci       Date:  2014-09-25

6.  Outcome Evaluation of a Subcutaneous Immunoglobulin Clinical Management Program.

Authors:  Julia Zhu; Gretchen Ayer; Heather S Kirkham; Chi-Chang Chen; Rolin L Wade; Swapna U Karkare; Chester H Robson; Jordan S Orange
Journal:  J Res Pharm Pract       Date:  2019 Apr-Jun
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.